• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Store » September 2002 – The CenterWatch Monthly : Volume 9, Issue 9, September 2002
September 2002 – The CenterWatch Monthly : Volume 9, Issue 9, September 2002

September 2002 – The CenterWatch Monthly : Volume 9, Issue 9, September 2002

$79.00

Product Details

Is Study Cost Management Harming Sites?

Investigative sites report that sponsors and CROs are setting unrealistic budgets and taking much longer to pay study grants. As a result, investigative sites face significant cash flow and profitability problems.

A Dynamic and Robust Medical Device Market

Clinical study grant spending continues to grow by more than 20% annually. Total grants for medical device trials will exceed $500 million in 2002. Most of the pressure to conduct trials for devices is coming from physicians, not the FDA.

Centrestage Europe: Trials Unit of North Manchester General to Service Three Hospitals

Though few hospitals in the United Kingdom have a clinical trials unit, those that do stand to reap handsome benefits following a merger with those hospitals that lack this capacity. Large clinical trials units can potentially gain a competitive edge in offering broadly based study conduct services.

Eye On: Kidney Cancer

Renal cell carcinoma arises from cells lining the renal tube. It affects about three of 10,000 people and accounts for about 85% of all kidney tumors and 3% of all adult cancers. It is now the 10th most common cancer in the United States. While treatment approaches include hormone therapy and arterial embolization, immunotherapy offers the most promise.

  • Month in Review
  • In the Pipeline
  • Opportunities Underway
  • TrialWatch
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing